Nothing Special   »   [go: up one dir, main page]

WO2020139175A3 - Моноклональные антитела против участка бета-цепи trbv9 человека - Google Patents

Моноклональные антитела против участка бета-цепи trbv9 человека Download PDF

Info

Publication number
WO2020139175A3
WO2020139175A3 PCT/RU2020/050024 RU2020050024W WO2020139175A3 WO 2020139175 A3 WO2020139175 A3 WO 2020139175A3 RU 2020050024 W RU2020050024 W RU 2020050024W WO 2020139175 A3 WO2020139175 A3 WO 2020139175A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
human
monoclonal antibodies
antibodies against
cell receptors
Prior art date
Application number
PCT/RU2020/050024
Other languages
English (en)
French (fr)
Other versions
WO2020139175A2 (ru
Inventor
Ольга Владимировна БРИТАНОВА
Дмитрий Борисович СТАРОВЕРОВ
Анна Валентиновна ЕВСТРАТЬЕВА
Алексей Константинович МИСОРИН
Тимофей Александрович НЕМАНКИН
Мария Александровна ЩЕМЕЛЕВА
Анна Константиновна ВЛАДИМИРОВА
Арина Витальевна АНИКИНА
Роман Алексеевич ИВАНОВ
Дмитрий Валентинович МОРОЗОВ
Павел Андреевич ЯКОВЛЕВ
Сергей Анатольевич ЛУКЬЯНОВ
Original Assignee
Закрытое Акционерное Общество "Биокад"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA202191813A priority Critical patent/EA202191813A1/ru
Priority to JOP/2021/0169A priority patent/JOP20210169A1/ar
Priority to KR1020217023568A priority patent/KR20220131489A/ko
Priority to CN202080016346.4A priority patent/CN114144432A/zh
Priority to BR112021012555-8A priority patent/BR112021012555A2/pt
Priority to MA53689A priority patent/MA53689B1/fr
Priority to US17/417,686 priority patent/US20220112286A1/en
Priority to CR20210354A priority patent/CR20210354A/es
Priority to CA3124813A priority patent/CA3124813A1/en
Priority to EP20734640.4A priority patent/EP3907239A4/en
Application filed by Закрытое Акционерное Общество "Биокад" filed Critical Закрытое Акционерное Общество "Биокад"
Priority to JP2021537707A priority patent/JP2022532274A/ja
Priority to MX2021007719A priority patent/MX2021007719A/es
Priority to SG11202106975VA priority patent/SG11202106975VA/en
Priority to PE2021001081A priority patent/PE20220217A1/es
Priority to AU2020204492A priority patent/AU2020204492A1/en
Publication of WO2020139175A2 publication Critical patent/WO2020139175A2/ru
Publication of WO2020139175A3 publication Critical patent/WO2020139175A3/ru
Priority to CONC2021/0008218A priority patent/CO2021008218A2/es
Priority to IL284370A priority patent/IL284370A/en
Priority to ZA2021/04357A priority patent/ZA202104357B/en
Priority to PH12021551532A priority patent/PH12021551532A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение относится к моноклональному гуманизированному антителу или его антигенсвязывающему фрагменту, которые специфически связываются с семейством TRBV9 Т-клеточных рецепторов человека. Изобретение также относится к нуклеиновой кислоте, кодирующей данное антитело или его антигенсвязывающий фрагмент, вектору экспрессии, способу получения антитела и применению антитела для лечения заболеваний или нарушений, связанных с семейством Т-клеточных рецепторов человека. Изобретение направлено на создание антител, которые могут быть использованы для терапии, в частности, анкилозирующем спондилите (АС или болезнь Бехтерева), целиакии и злокачественных заболеваний крови, в патогенез которых вовлечены ТКР семейства TRBV9.
PCT/RU2020/050024 2018-12-25 2020-02-20 Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения WO2020139175A2 (ru)

Priority Applications (19)

Application Number Priority Date Filing Date Title
JP2021537707A JP2022532274A (ja) 2018-12-25 2020-02-20 ヒトｔｒｂｖ９のベータ鎖領域に対するモノクローナル抗体
JOP/2021/0169A JOP20210169A1 (ar) 2018-12-25 2020-02-20 أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري
CN202080016346.4A CN114144432A (zh) 2018-12-25 2020-02-20 针对人TRBV9的β链区域的单克隆抗体
BR112021012555-8A BR112021012555A2 (pt) 2018-12-25 2020-02-20 Anticorpos monoclonais contra a região de cadeia beta do trbv9 humano
MA53689A MA53689B1 (fr) 2018-12-25 2020-02-20 Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application
US17/417,686 US20220112286A1 (en) 2018-12-25 2020-02-20 Monoclonal antibodies against the beta chain region of human trbv9
CR20210354A CR20210354A (es) 2018-12-25 2020-02-20 Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso
MX2021007719A MX2021007719A (es) 2018-12-25 2020-02-20 Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso.
EP20734640.4A EP3907239A4 (en) 2018-12-25 2020-02-20 MONOCLONAL ANTIBODIES AGAINST THE BETA CHAIN REGION OF HUMAN TRBV9
EA202191813A EA202191813A1 (ru) 2018-12-25 2020-02-20 Моноклональные антитела против участка бета-цепи trbv9 человека
KR1020217023568A KR20220131489A (ko) 2018-12-25 2020-02-20 인간 trbv9의 베타 쇄 영역에 대한 단일클론 항체
CA3124813A CA3124813A1 (en) 2018-12-25 2020-02-20 Monoclonal antibodies against the beta chain region of human trbv9
SG11202106975VA SG11202106975VA (en) 2018-12-25 2020-02-20 Monoclonal antibodies against the beta chain region of human trbv9
PE2021001081A PE20220217A1 (es) 2018-12-25 2020-02-20 Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso
AU2020204492A AU2020204492A1 (en) 2018-12-25 2020-02-20 Monoclonal antibodies against the beta chain region of human TRBV9
CONC2021/0008218A CO2021008218A2 (es) 2018-12-25 2021-06-23 Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso
IL284370A IL284370A (en) 2018-12-25 2021-06-24 Monoclonal antibodies against the beta chain region of human TRBV9
ZA2021/04357A ZA202104357B (en) 2018-12-25 2021-06-24 Monoclonal antibodies against the beta chain region of human trbv9
PH12021551532A PH12021551532A1 (en) 2018-12-25 2021-06-25 Monoclonal antibodies against the beta chain region of human trbv9

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018146031A RU2712251C1 (ru) 2018-12-25 2018-12-25 Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
RU2018146031 2018-12-25

Publications (2)

Publication Number Publication Date
WO2020139175A2 WO2020139175A2 (ru) 2020-07-02
WO2020139175A3 true WO2020139175A3 (ru) 2020-10-29

Family

ID=69184123

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/RU2019/050258 WO2020091635A2 (ru) 2018-12-25 2019-12-24 Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения
PCT/RU2020/050024 WO2020139175A2 (ru) 2018-12-25 2020-02-20 Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/RU2019/050258 WO2020091635A2 (ru) 2018-12-25 2019-12-24 Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения

Country Status (25)

Country Link
US (1) US20220112286A1 (ru)
EP (1) EP3907239A4 (ru)
JP (1) JP2022532274A (ru)
KR (2) KR20210119404A (ru)
CN (2) CN113646333A (ru)
AR (1) AR117734A1 (ru)
AU (1) AU2020204492A1 (ru)
BR (1) BR112021012555A2 (ru)
CA (2) CA3127767A1 (ru)
CL (1) CL2021001705A1 (ru)
CO (2) CO2021008218A2 (ru)
CR (1) CR20210354A (ru)
EA (1) EA202191813A1 (ru)
EC (1) ECSP21046333A (ru)
IL (1) IL284370A (ru)
JO (1) JOP20210169A1 (ru)
MA (1) MA53689B1 (ru)
MX (1) MX2021007719A (ru)
PE (1) PE20220217A1 (ru)
PH (1) PH12021551532A1 (ru)
RU (1) RU2712251C1 (ru)
SG (1) SG11202106975VA (ru)
TW (1) TW202039574A (ru)
WO (2) WO2020091635A2 (ru)
ZA (1) ZA202104357B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN116510006A (zh) * 2022-01-31 2023-08-01 拜奥卡德联合股份公司 抗trbv9抗体的药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006758A1 (en) * 1988-12-15 1990-06-28 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t cell antigen receptor
RU2539032C2 (ru) * 2009-06-25 2015-01-10 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения искусственного иммунитета

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
EP3202784A1 (en) * 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
RU2694412C9 (ru) * 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006758A1 (en) * 1988-12-15 1990-06-28 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t cell antigen receptor
RU2539032C2 (ru) * 2009-06-25 2015-01-10 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения искусственного иммунитета

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOYABE S. ET AL.: "Biclonal expansion of T cells infected with monoclonal Epstein- Barr virus (EBV) in a patient with chronic, active EBV infection", CLINICAL & EXPERIMENTAL IMMUNOLOGY, vol. 13 4, no. 1, October 2003 (2003-10-01), pages 92 - 97, XP055622974, DOI: 10.1046/j.l365- 2249.2003.02270.x *

Also Published As

Publication number Publication date
KR20220131489A (ko) 2022-09-28
JOP20210169A1 (ar) 2023-01-30
CA3124813A1 (en) 2020-07-02
ZA202104357B (en) 2022-09-28
WO2020139175A2 (ru) 2020-07-02
KR20210119404A (ko) 2021-10-05
PH12021551532A1 (en) 2022-02-28
CN114144432A (zh) 2022-03-04
AR117734A1 (es) 2021-08-25
CL2021001705A1 (es) 2022-01-28
US20220112286A1 (en) 2022-04-14
MX2021007719A (es) 2022-03-25
CA3127767A1 (en) 2020-05-07
WO2020091635A3 (ru) 2020-10-22
MA53689B1 (fr) 2023-03-31
CO2021009689A2 (es) 2021-08-09
CR20210354A (es) 2021-12-20
MA53689A1 (fr) 2022-06-30
SG11202106975VA (en) 2021-07-29
IL284370A (en) 2021-08-31
CN113646333A (zh) 2021-11-12
EP3907239A4 (en) 2022-10-05
BR112021012555A2 (pt) 2021-09-14
ECSP21046333A (es) 2021-07-30
CO2021008218A2 (es) 2021-07-30
EA202191813A1 (ru) 2021-10-07
WO2020091635A2 (ru) 2020-05-07
EP3907239A2 (en) 2021-11-10
RU2712251C1 (ru) 2020-01-27
AU2020204492A1 (en) 2021-08-12
PE20220217A1 (es) 2022-02-02
TW202039574A (zh) 2020-11-01
JP2022532274A (ja) 2022-07-14

Similar Documents

Publication Publication Date Title
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
PH12021551535A1 (en) Monoclonal antibodies that bind specifically to human trbv9
NZ610734A (en) Human antibodies to the glucagon receptor
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
EA202091747A1 (ru) Составы антитела b7-h4
ZA202008095B (en) Humanized antibodies against psma
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
JOP20210265A1 (ar) الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
PH12021551532A1 (en) Monoclonal antibodies against the beta chain region of human trbv9
JP2021500916A5 (ru)
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
WO2023004036A3 (en) Anti-fsh antibodies for neurodegenerative diseases
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.
ECSP19018367A (es) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
MX2022000332A (es) Anticuerpos contra el receptor de muerte celular programada pd-1 humano.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3124813

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: NC2021/0008218

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2021537707

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021012555

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020734640

Country of ref document: EP

Effective date: 20210726

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20734640

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020204492

Country of ref document: AU

Date of ref document: 20200220

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112021012555

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210624